MMP-14 inhibitor (SomantiX/PharmBioTec/Pharmacelsus vv)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMMP-14 inhibitor (SomantiX/PharmBioTec/Pharmacelsus vv)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 14 inhibitors
TargetsMatrix metalloproteinase 14
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSomantix BV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmBioTec GmbHSomantix BVPharmacelsus GmbH
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A